The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

Article ID	Journal	Published Year	Pages	File Type
5903068	Metabolism	2016	10 Pages	PDF

Abstract

These findings suggest that the insulin-sensitizing effects of SGLT2 inhibition contribute to improvements in glycemic control in insulin-resistant states.

Keywords

T2D OGTT HGP SOCS FPG DIO SGLT stearoyl-CoA desaturase HbA1c ZDF PTP GDR FAS SCD Hprt DPP Oral glucose tolerance test fatty acid synthase Hepatic glucose production Type 2 diabetes dipeptidyl peptidase suppressor of cytokine signaling Fasting plasma glucose Insulin resistance DPP-4 inhibitor SGLT2 inhibitor Glucose disposal rate Glycated hemoglobin hypoxanthine phosphoribosyltransferase Protein tyrosine phosphatase diet-induced obese Zucker Diabetic Fatty Glycemic control

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology

The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

Authors

Matthias Kern, Nora Klöting, Michael Mark, Eric Mayoux, Thomas Klein, Matthias Blüher,